CompletedNCT01998958
Intranasal Esketamine for Treatment-Resistant Depression
About this title
Read the official source —Medication studyAges 20–64Multiple countries
Understand this study
Who was this study for?
Listed age limits: 20 years to 64 years.
- Listed locations
- Birmingham and 24 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateStarted: January 27, 2014
- Recruitment status
- Completed
- Enrollment listed in the registry
- 108
- Sponsor
- Janssen Research & Development, LLC
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States, Belgium, Japan
- Age range
- From 20 Years to 64 Years
- Official registry ID
- NCT01998958
- Official title
Show the full official title
A Double-Blind, Doubly-Randomized, Placebo-Controlled Study of Intranasal Esketamine in an Adaptive Treatment Protocol to Assess Safety and Efficacy in Treatment-Resistant Depression (SYNAPSE)
Get this study by email
Recruitment & locations
CompletedBirmingham, United States · Garden Grove, United States · Hartford, United States
22 more locations
- Jacksonville, United States
- Tampa, United States
- Atlanta, United States
- Chicago, United States
- Hoffman Estates, United States
- Rockville, United States
- Cedarhurst, United States
- New York, United States
- Allentown, United States
- Philadelphia, United States
- Memphis, United States
- Lede, Belgium
- Akita, Japan
- Hiroshima, Japan
- Ichikawa, Japan
- Kanzaki, Japan
- Kashihara, Japan
- Kitakyushu, Japan
- Kodaira, Japan
- Kumamoto, Japan
- Nagano, Japan
- Shibukawa, Japan
Questions about this study
Who is behind this study?
The study sponsor is Janssen Research & Development, LLC.
Did this study involve medication?
Yes. The study involved medication, including Esketamine 14 mg, Esketamine 28 mg, Esketamine 56 mg, Esketamine 84 mg and Placebo.
Who was this study for?
Listed age limits: 20 years to 64 years.
